Open Letter to Leaders of G7, G20, BRICS and All Nations on Finalizing the WHO Pandemic Agreement’s Pathogen Access and Benefit Sharing Annex

Why It Matters

Finalizing the PABS annex gives WHO a enforceable mechanism to share pathogen data and ensure equitable access to resulting medical tools, directly strengthening global health security and averting massive economic disruption.

Key Takeaways

• PABS annex is the last hurdle for WHO Pandemic Agreement activation
• Leaders must signal top‑level political will to close remaining gaps
• Equity ensures countries that share pathogens receive vaccines and treatments
• One‑in‑four chance of a pandemic within ten years drives urgency
• COVID‑19 cost over $13 trillion; early‑response system is a fraction

Pulse Analysis

The WHO Pandemic Agreement, adopted in 2022, was hailed as a historic step toward coordinated global health defense after COVID‑19 exposed glaring gaps in pathogen surveillance and data sharing. Central to the pact is the Pathogen Access and Benefit‑Sharing (PABS) annex, which would codify rapid exchange of genetic sequences and ensure that any medical counter‑measures derived from shared samples are made available to the contributing nations. By institutionalizing these processes, the annex aims to transform ad‑hoc, crisis‑driven negotiations into a stable, pre‑agreed framework that can accelerate vaccine and therapeutic development when the next zoonotic spillover occurs.

Equity lies at the heart of the PABS proposal. Developing countries, often the source of novel pathogens, have long feared that sharing samples would benefit only wealthier nations while they remain left behind. The annex seeks to lock in a fair bargain: prompt sharing in exchange for guaranteed access to vaccines, diagnostics and treatments. This not only addresses moral imperatives but also makes strategic sense; containing an outbreak at its source is far cheaper—both in lives and in the estimated $13 trillion economic loss from COVID‑19—than fighting a pandemic after it spreads globally. Predictable rules also lower investment risk for biotech firms, encouraging rapid innovation.

Political momentum, however, remains fragile. Negotiators have a narrow window from 6 to 17 July to bridge technical disputes over benefit allocation, governance structures and sovereign rights. The open letter calls on heads of state to signal top‑level commitment, framing the deadline as a matter of urgency given a projected one‑in‑four chance of a pandemic within the next decade. If the annex is ratified, the WHO will finally possess a binding tool to mobilize the international community, turning the lessons of COVID‑19 into a durable safeguard for future generations.